TYTN - A Bottom Buster With Benefits

Tytan Holdings, stock ticker TYTN, is not your run of the mill bottom buster.  Sure the stock is trading just off of recent lows, but the company and its stock is at the beginning of ,what could prove to be, an impressive rally.  Let's highlight some of the positive aspects concerning TYTN:

• Stock float 160,000,000 yet trades like much less shares in circulation
• Company just getting started and stock has very little investor interest at the moment
• Company updated many filings at Pink Sheets to become current 
• Company has $250,000 in cash and NO DEBT

There are many things that makes TYTN an exciting stock heading into the end of the year.

This stock will run at some point, it will only be a matter of time.  Too much effort has gone into this stock, with all the pink sheet updates, for it not to mount a nice rally.

Volume has been sporadic and light.  A push above $.01 would not be a surprise.

TYTN closed at $.0015 on Tuesday with a bid of $.0013.

Keep it on your watchlist.

NXHD - Beware Of The New Pump

Just type a search for NXHD on this blog and you will find most of the information you will ever need concerning the stock.

Today's press release does not change any of the facts about the stock, most notably its bidless nature, equating to a stock that is easily purchased at $.0001 but impossible to get out of.  Hence shareholders are stuck holding shares in a stock that has over 10 billion outstanding as of June, with likely a heck of a lot more dumped into the market since then. 

If holding worthless share certificates is a hobby of yours, than NXHD might just be the stock for you to focus your hobby energies on.

Nexia Signs Three Letters of Intent to Acquire Residential Properties in Ogden, Utah
SALT LAKE CITY, UT, Nov 10, 2009 (MARKETWIRE via COMTEX) -- Nexia Holdings, Inc. (PINKSHEETS: NXHD) reported that it has signed three letters of intent to acquire three residential properties located in the Ogden, Utah area. The purchase prices for the properties are as follows: $95,000, $125,000, and $170,000; the first two are single family residences and the last property is a triplex. Total compensation in the form of 92,800 restricted shares of Series C Preferred Stock of Nexia would be issued to the sellers upon the closing of the final purchase of the properties according to the terms of the letters of intent. These agreements are part of Nexia Holdings' real estate acquisition program and show the promise of the program even during the current downturn in the overall real estate market. Nexia's President, Richard Surber, stated, "I am hopeful that we can get back to growing this program and developing these properties into income sources for Nexia's real estate operations over the next 12 to 14 months."
About Nexia Holdings Inc.
Nexia Holdings Inc. (PINKSHEETS: NXHD), headquartered in Salt Lake City, Utah, is a diversified holdings company with operations in entertainment, real estate and health & beauty. Nexia owns a majority interest in Landis Salons, Inc., www.landissalons.com, a hair salon built around the world-class AVEDA(TM) product line. For more information, visit http://www.nexiaholdings.com.
Nexia strongly encourages the public to read the above information in conjunction with its Form 10-K for December 31, 2007 and the subsequent quarters of 2008. Nexia's disclosures can be viewed at www.nexiaholdings.com and www.sec.gov. The success of the above strategy is conditioned upon a substantial increase in liquidity of Nexia's common stock, an eventual recovery in the real estate markets that Nexia invests in and many other factors which will emerge as Nexia executes upon its acquisition strategy.
SOURCE: Nexia Holdings, Inc.

Copyright 2009  Marketwire, Inc., All rights reserved.

-0-

SUBJECT CODE:     Real Estate and Construction:Residential Real Estate
                  Real Estate and Construction:Commercial Real Estate

Stocks To Watch Tuesday Nov. 10th - ECSI, HTDS, BEHL

ECSI had a decent day on Monday and we are awaiting news on this stock.  News be the fuel that ignites the next big rally for this stock.  Until then $.015 - $.035 is the range to watch.

HTDS had big news today.  The stock held most of its gains.  Expect a big gap at the open followed by some selling as the day progresses.

BEHL another red day today means a good chance it bounces tomorrow.  $.02 is the target for any short term bounce.  Would like to see $.03 again to confirm a rally.

The Guru Bottom Buster

Readers The Guru Has A Stock That Appears To Have Bottomed.

I'll post this stock sometime tomorrow or Wednesday.

If you have a stock you think has bottomed after a sell-off, is ripe for a rally, or has recently undergone some positive changes, please email me at pennystockforums@gmail.com.  With all the stocks I stare at every day, I am sure I miss a few.

This bottom buster stock, I am ready to reveal soon, has fallen 90% under light volume.  Just seeing if its dilution or an impatient shareholder.  I don't like posting dilutive issues.

The point is: check back tomorrow to see what the stock is.

HTDS - Hard To Treat Diseases and Novartis - An Amazing Combination

When a $.01 stock announces that a $122 billion market cap company has purchased $125 million in assets from it, a smart investor should hop on the train. Novartis, ticker NVS, is trading at $53.58 a share and apparently is doing business with HTDS a stock that, until today's news, was trading around $.01.

Let's look at the cards HTDS is playing.

#1 they are playing the swine flu H1N1 card.
#2 they are playing the huge multi-national $100+ billion company card.

Either way its a win for HTDS shareholders. Forget the long term and question only how long you will play this news. Today's volume illustrates the interest in this stock.

You can expect some more positive movement on this news.

Just be wary of it. When a company with a stock at $.01 claims to be doing business with a billion dollar company trading at $53.58 a share something is probably amiss. But that doesn't mean you can't play the move.




Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million

SHENZHEN, China, Nov 09, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. The comments were made by Novartis' CEO, Daniel Vasella, in an interview with The Wall Street Journal. http://www.chinabiotoday.com/articles/20091103_1

HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA.

Terry Yuan, HTDS' President/CEO said "We believe that when you start to appreciate what Novartis' commitment to our partner in China fully means, and the see the large financial commitment to our partner just for the China market, you can begin to appreciate the enormous value to HTDS of our exclusive international marketing and sales relationship with Zhejiang Tianyuan Bio-Pharmaceutical. Further, the more you appreciate this value, the more you will find yourself understanding our value to them when they appointed us exclusive agent for international marketing and sales. As Mellow Hope owns all of registrations, clinical trials and brands for Zhejiang Tianyuan's international markets, the new Novartis-Zhejiang-Tianyuan entity will continue to leverage our assets and expertise in its international market. The Novartis purchase was announced by Novartis-Zhejiang-Tianyuan on November 4, 2009 (see link below) http://www.marketwatch.com/story/novartis-to-buy-85-of-chinese-vaccines-producer-2009-11-04?siteid=yhoof2. HTDS management, elected not to release this immediately, to allow the HTDS management and its advisors to digest and analyse the long term effects of this transaction for HTDS. HTDS management is very optimistic and foresees its relationship and business with Zhejiang Tianyuan will only be further strengthened by the participation of Novartis."

Novartis reports that it has made the purchase of a majority interest in Zhejiang Tianyuan through proposed acquisition of a majority stake for US$125 million to expand its human vaccines presence in China. Zhejiang Tianyuan is a privately-held vaccines company providing a competitive product portfolio and pipeline in China, where Novartis has a limited vaccines presence. Tianyuan and Novartis are to collaborate on building a vaccines industry leader targeting unmet medical needs in China, the world's third-largest vaccines market. Acquisition of 85% stake in Tianyuan for approximately US$125 million will require Chinese regulatory and government approvals.

Tianyuan is a privately-owned vaccine company offering a range of marketed vaccine products in China and R&D projects focused on various preventable viral and bacterial diseases. Tianyuan has been delivering dynamic and profitable growth, having more than doubled its net sales to approximately US$25 million in 2008.

About Hard To Treat Diseases (HTDS)

Stocks To Watch Monday November 9th - ECSI, BEHL, ZENG, NTHD

NTHD has some rumors circulating about some concrete groundwork toward a business plan.  Rumors can be just as powerful as bonafide news.  Let's see what happens the next few days with NTHD.

BEHL fell like a stone on Friday.  Could it be the end of something good or the start of a nice bounce.  We are leaning toward some more red in the days ahead.

ZENG also has fallen from our target price and appears to be lacking support.  ZENG is now a stock to avoid going forward as the accumulation phase is likely over.

ECSI could mount a significant run the next few days ahead of an expected merger press release.  Keep this one on your watch list.

ECSI - Merger/Acquisition News To Hit The Wires Any Day Now

Some readers might remember HMDI from a month back. (If not click here)


The stock moved up 101,000% in one trading session.  How's that for a ROI?  ECSI could see a similar share price explosion, and the best part is we know the merger news is coming!


Wouldn't it have been great to have known the HMDI merger press release was coming out before everyone else? If you have read recent business news we are all realizing this is how the hedge funds, such as Galleon, have been making money all these years... by beating investors to the punch. Of course insider trading is illegal and the SEC is punishing those who profited from it, but in the case of ECSI we already know the merger is coming via a September press release, although it appears not too many other people do, and this gets us one big step ahead of everyone else.

Back in September ECSI released some news that garnered very little attention at the time(press release is below the post for your reading pleasure) about a pending merger.  The stock has since seen a few pops to $.02 or so before falling back to the sub $.005 range. All the trading action has been on very light volume. In essence this stock has completely missed investors radars. A merger press release for a dormant shell stock is an almost guaranteed big mover.  1,000% would not be a surprise at all after seeing how HMDI went 101,000%!   ECSI is to have completed this merger within the last few weeks, which means a press release is coming any day now.

That merger press release will almost certainly move ECSI substantially higher than its recent trading range.

Also consider that ECSI was trading at $1.70 as a shell and has slowly sold down to $.004 over the last few years on very light and sporadic volume.  Now ECSI will become a stock that represents an active and exciting entity, instead of a dormant shell stock, which should send the stock back up to the levels in which it came from.

With ECSI investors are getting a chance to play the HMDI type merger press release before the crowd.  These penny stocks can prove to be quite a gamble, but when you get some of the cards dealt to you in advance the odds can change in your favor.

Keep your eye on ECSI and new developments concerning the stock.  It should be a big mover in the coming days and weeks.









ECash Inc. Signs Letter of Intent to Acquire MetaHealth Inc. Assets
Las Vegas, NV, Sep 16, 2009 (PRWeb.com via COMTEX) -- ECash (ECSI.PK) today announced that they have signed a letter of intent with Metahealth Inc. to acquire the company's assets. The acquisition is the next step for ECash as they enter the health care supply industry. As the Baby Boomer generation begins reaching age 65 by or before 2011, the healthcare industry will increasingly demand greater amounts of medical equipment and health care supplies. ECash intends to invest in one of the most lucrative areas of health care as the country's largest demographic reaches old-age.
Metahealth, Inc. is a pharmaceutical development company whose mission is to develop, manufacture and market a wide range of generic prescription drug products for the health care market.
"The acquisition of Metahealth is a big step forward in our company's development," said Christian Diesveld, VP Business Development of ECash. "Metahealth is aptly positioned to benefit as brand name drugs lose their market exclusivity through patent expiration."
Metahealth is currently active in the following areas: central nervous system drugs such as anti-convulsants and anti-psychotics, topical dermatology drugs such as topical antibiotics, anti-fungals and anti-inflammatories, hormonal drugs such as steroidal treatments and a variety of other drugs.
Generic pharmaceuticals play a large role in health care systems as many governments encourage and require the use of generic substitutes in order to control costs.
Closing is anticipated within the next three to four weeks once management completes due diligence.
Contact:
Kevin Mercuri E Cash Inc. 212-901-6914 x701
Cautionary Statements Concerning Forward-Looking Information This press release contains forward-looking statements regarding the current expectations of ECSI. Such forward-looking statements are not guarantees of future performance or events and involve risks and uncertainties. Actual results may differ materially from those described in such forward-looking statements as a result of various factors. ECSI does not undertake any obligation to update the forward-looking statements contained herein, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
###
Read the full story at http://www.prweb.com/releases/2009/09/prweb2889004.htm.